Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015

On November 20, 2026 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported positive updated U.S. Phase 1 monotherapy and initial combination data reinforcing the best-in-class potential of pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. The Company confirms its plans to initiate a potentially registration-enabling trial in 2L+ lung cancer in the first half of 2027 and a Phase 3 trial in 1L lung cancer in the second half of 2027 to first half of 2028 timeframe; and is accelerating the planned initiation of a Phase 3 trial in 1L pancreatic cancer to the first half of 2027. The Company also announced encouraging initial U.S. Phase 1 monotherapy data for potential first-in-class pan-KRAS inhibitor ERAS-4001, supporting its combination potential with ERAS-0015.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These compelling results highlight the strength and breadth of ERAS-0015’s clinical activity across several tumor types," said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. "We are particularly encouraged by confirmed responses in common KRAS mutation subtypes, including G12D and G12V, which together occur in nearly 70% of patients with pancreatic cancer. Importantly, we believe the robust clinical activity observed in this heavily pretreated population, which included a high proportion of patients whose tumors harbored less sensitive mutations, compares favorably with reported activity for other pan-RAS and mutant-selective inhibitors, subject to the limitations of cross-study comparisons. Additionally, we believe these efficacy results, coupled with generally well-tolerated safety data and low rates of dose interruptions, reductions, and discontinuations at 32 mg once daily, support advancing ERAS-0015 toward multiple potentially registration-enabling trials."

Dr. Lim continued, "Early combination data demonstrating favorable tolerability results with chemotherapy, an immune checkpoint inhibitor, and an anti-EGFR antibody, together with preliminary clinical activity for ERAS-4001, strengthen our rationale for expanding ERAS-0015’s combination potential. We expect 2027 to be an important year for our RAS-targeting franchise as we plan to initiate potentially registration-enabling clinical trials in pancreatic and lung cancers and advance combination dose-escalation trials, including the planned ERAS-0015 plus ERAS-4001 combination."

Key U.S. Phase 1 interim results for ERAS-0015 (AURORAS-1):

As of the data cutoff date, ERAS-0015 monotherapy at the pharmacologically active doses (PAD) of 16-32 mg once daily (QD) (N=122) was generally well-tolerated with favorable safety data, and demonstrated encouraging activity in key KRAS G12X tumors. Monotherapy responses shown are confirmed. All patients with responses at 32 mg QD in all tumor types remained on treatment.1,2

ERAS-0015 Monotherapy Showed Strong Anti-Tumor Activity Across Advanced KRAS-Mutant Cancers

KRAS G12X pancreatic ductal adenocarcinoma (PDAC) at 32 mg QD in the second-line or greater (2L+) setting1,2
44% confirmed objective response rate (ORR) across all patients (N=25) with KRAS G12X mutations; 84% were treated in the third-line or later (3L+) setting and 44% had G12R mutations
69% confirmed ORR in patients (N=13) with KRAS G12D or G12V PDAC, which represent nearly 70% of patients with PDAC. Of these patients, 77% were treated in 3L+

63% confirmed ORR (N=8) in patients with KRAS G12D
80% confirmed ORR (N=5) in patients with KRAS G12V
All (11 of 11) patients with confirmed responses and 6 of 11 patients with stable disease remained on treatment
KRAS G12X non-small cell lung cancer (NSCLC)1,2
60% confirmed ORR (N=5) at 32 mg QD and 58% confirmed ORR (N=12) across the PAD range of 16-32 mg QD in the 2L or 3L setting following an immune checkpoint inhibitor and platinum-based chemotherapy (post-ICI/platinum)
Activity was observed across multiple KRAS mutation subtypes at 32 mg QD in the 2L+ setting:

60% confirmed ORR (N=5) in patients with KRAS G12D mutations
50% confirmed ORR (N=4) in patients with KRAS G12V mutations
At 32 mg QD in the 2L+ setting, all (5 of 5) patients with confirmed responses and all (5 of 5) patients with stable disease remained on treatment
KRAS G12X biliary tract cancer (BTC) at 32 mg QD in the 1L+ setting1
75% confirmed ORR (N=4)
All (3 of 3) patients with confirmed responses remained on treatment

ERAS-0015 Monotherapy Continued to Be Generally Well-Tolerated with Favorable Safety Data in Expanded Patient Population1,5

Frequency and severity of treatment-related adverse events (TRAEs) remained consistent with the Company’s April and July 2026 interim data disclosures
Mostly low-grade TRAEs with no dose-limiting toxicities (DLTs) and low rate of dose interruptions, reductions, and discontinuations due to TRAEs
At 32 mg QD (N=54), TRAEs led to dose interruptions in 13.0% of patients and dose reductions in 16.7% of patients, and there were no dose discontinuations (0% of patients)
100% median relative dose intensity (RDI) at 32 mg QD
Early ERAS-0015 Combination Data Support Further Development and Potential for Differentiation with Standard-of-Care Therapies3

ERAS-0015 plus gemcitabine + nab-paclitaxel (Days 1 and 15):
Generally well tolerated with favorable safety data and no unexpected safety signals
The DLT window was cleared through the 16 mg QD ERAS-0015 cohort with no DLTs
Currently dosing the 24 mg QD ERAS-0015 dose escalation cohort
Efficacy data not yet available
Clinical data support further development in 1L PDAC
ERAS-0015 plus pembrolizumab:
Generally well tolerated with favorable safety data and no unexpected safety signals
The DLT window was cleared through the 32 mg QD ERAS-0015 cohort with no DLTs
Multiple responses observed in multiple solid tumor types in dose escalation
Clinical data support further development in 1L NSCLC, including combination with carboplatin/pemetrexed/pembrolizumab (initiated in Q4)
ERAS-0015 plus panitumumab:
16 mg QD ERAS-0015 was generally well tolerated with favorable safety data and no unexpected safety signals
Multiple responses were observed in dose escalation in patients with KRAS G12X colorectal cancer (CRC), including 2 ongoing confirmed partial responses (PR) in 2 patients treated at 24 mg QD who then dose reduced to 16 mg QD, and 1 unconfirmed PR (uPR) in 4 patients treated at 16 mg QD
Combination dose exploration ongoing; plan to make dose selection in 2027

Encouraging Preliminary ERAS-4001 Phase 1 Data Support Planned Combination with ERAS-00154

Favorable safety and tolerability data with predominantly low-grade adverse events and no TRAEs leading to treatment discontinuation
Pharmacokinetic (PK) results were encouraging and support continued dose escalation
Preliminary monotherapy antitumor activity supports ERAS-4001’s potential as a combination partner for ERAS-0015
Nonclinical data demonstrated that the combination of ERAS-0015 and ERAS-4001 targets both active- and inactive-state KRAS and exhibits synergistic activity in KRAS G12X-driven models, providing a rationale for further evaluation of this combination
Key Anticipated Milestones

ERAS-0015: AURORAS-1 and Phase 3 Trials

Potentially registration-enabling trial in patients with 2L+ RAS-mutant NSCLC expected to initiate in the first half of 2027
Phase 3 trial in patients with 1L PDAC accelerated to initiate in the first half of 2027
Phase 3 trial in patients with 1L RAS-mutant NSCLC expected to initiate in the second half of 2027 to the first half of 2028
Combination dose escalation and expansion data expected in 2027
ERAS-4001: BOREALIS-1 Trial

Initiation of combination dose escalation trial with ERAS-0015 planned for 2027

¹ Data cutoff date (DCO) September 1, 2026
² Includes responses confirmed after the data cutoff date
3 DCO October 14, 2026
4 As of November 9, 2026
5 As disclosed by the Company in April 2026, one Grade 3 TRAE of pneumonitis progressed to Grade 5 after withdrawal of supportive care per patient decision. The patient was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma who received 24 mg of ERAS-0015. The patient had pulmonary metastases, a history of right lung cryoablation and no history of lung radiation. The patient presented to the ER approximately a month after starting ERAS-0015 with Grade 3 pneumonitis that was treated aggressively with immediate discontinuation of ERAS-0015, high dose steroids and infliximab. The patient requested withdrawal of supportive care and ultimately died of the event. No additional Grade 5 TRAEs have occurred

Virtual Investor Event Webcast Information
Erasca will hold a virtual investor event today, Friday, November 20, 2026 at 8:00 a.m. Eastern Time. To register for the event please click here. The live webcast and replay may be accessed by referring to Erasca’s website at Erasca.com/events.

About ERAS-0015
ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile and has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic pancreatic adenocarcinoma. The ongoing AURORAS-1 Phase 1 trial is evaluating ERAS-0015 as a monotherapy and in combination with other therapies in patients with RAS-mutant solid tumors. Clinical data have demonstrated robust monotherapy activity in pancreatic ductal adenocarcinoma (PDAC) and KRAS-mutant non-small cell lung cancer (NSCLC), and encouraging initial activity in KRAS-mutant colorectal cancer (CRC) in combination with an anti-EGFR antibody. ERAS-0015 has been generally well-tolerated with favorable safety data and with well-behaved pharmacokinetics (PK). Emerging tolerability data with chemotherapy, pembrolizumab, and panitumumab support combination development at ERAS-0015 doses within the pharmacologically active dose (PAD) range. ERAS-0015 is also designed to inhibit RAS wildtype variants, which may contribute to resistance to mutant-selective approaches. Together, these findings support its potential as both a monotherapy and backbone for combination regimens.

About ERAS-4001
ERAS-4001 is an investigational, oral, highly potent, and selective pan-KRAS inhibitor with a potential first-in-class and best-in-class profile. Erasca is evaluating ERAS-4001 in the BOREALIS-1 Phase 1 trial in patients with KRAS-mutant solid tumors. Preliminary clinical data have demonstrated favorable safety and tolerability across doses evaluated. Promising preliminary pharmacokinetic (PK) data have been observed. In nonclinical studies, ERAS-4001 showed potent activity against both guanosine triphosphate (GTP)-bound (active state) and GDP-bound (inactive state) KRAS and induced tumor regression in multiple KRAS-mutant models. ERAS-4001 also inhibited wildtype KRAS, which may contribute to resistance to mutant-selective approaches, while sparing wildtype HRAS and NRAS. Preliminary monotherapy antitumor activity supports ERAS-4001’s potential as a combination partner for ERAS-0015.

(Press release, Erasca, NOV 20, 2026, View Source [SID1234675035])

Vesicor Therapeutics and Black Hawk Acquisition Corporation Announce Closing of Business Combination

On November 20, 2026 Vesicor Therapeutics Holdings, Inc. ("Vesicor" or the "Company"), an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles, reported the closing of its previously announced business combination with Black Hawk Acquisition Corporation (Nasdaq: BKHA) ("Black Hawk"). The transaction was approved by Black Hawk’s shareholders at an extraordinary general meeting held on October 13, 2026 and closed on November 19, 2026. In connection with the closing, Black Hawk domesticated from the Cayman Islands to Delaware and changed its name to Vesicor Therapeutics Holdings, Inc. The Company’s common stock is expected to begin trading on the Nasdaq Capital Market under the ticker symbol "VESI" on November 23, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vesicor will be led by Michael Tolentino, MD, Chief Executive Officer; Luo Feng, PhD, Founder, Director and Chief Scientific Officer; Mitch Creem, MHA, Chief Financial Officer; and Warren Hosseinion, Jr., Chief Operating Officer. The Company’s Board of Directors consists of Warren Hosseinion, Sr., MD (Chairman), Luo Feng, PhD, Oded Levy, Frederick Woodruff Field and Qi Ouyang.

"Closing this transaction gives Vesicor access to the public markets at the point where the Company needs it most, as we prepare to begin IND-enabling studies for ecm-RV/p53," said Warren Hosseinion, Sr., MD, Chairman of the Board. "I want to thank our shareholders and the Vesicor team for the work that brought us here. Our focus now is execution."

"I founded Vesicor in 2008 with the goal of developing p53-based cancer therapeutics using precision-engineered microvesicles," said Luo Feng, PhD, Founder, Director and Chief Scientific Officer. "ecm-RV/p53 reflects many years of research, and we are focused on building on that foundation as we seek to advance the program toward clinical evaluation."

"Our priority as a public company is clear: advance ecm-RV/p53 through IND-enabling studies and toward an IND submission to the FDA," said Michael Tolentino, MD, Chief Executive Officer. "We have a defined goal, an experienced team and a board that has the skills to advance the priorities of the Company. We look forward to reporting our progress to shareholders."

Advisors

Celine & Partners, P.L.L.C. and Ogier Global (Cayman) Limited served as legal counsel to Black Hawk. D. Boral Capital LLC served as the capital markets advisor to Black Hawk. PW Richter PLC, Winston Taylor LLP, and Shartsis Friese LLP served as legal counsel to Vesicor.

(Press release, Vesicor Therapeutics, NOV 20, 2026, View Source [SID1234675051])

Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma

On November 20, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival (OS) compared to treatment of physician’s choice (TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel) in the treatment of patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. TroFuse-015 represents the first time a TROP2-directed ADC has demonstrated an OS benefit in a global Phase 3 trial in this patient population, where there is significant unmet need. These data will be presented at an upcoming medical meeting and shared with regulatory authorities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At final analysis, sac-TMT demonstrated a statistically significant and clinically meaningful improvement in OS compared to TPC for these patients who have received two or more prior lines of systemic therapy. Results were generally consistent across subgroups regardless of TROP2 expression status. Sac-TMT did not meet the secondary endpoint of progression-free survival (PFS) assessed by blinded independent central review (BICR). Additionally, sac-TMT showed a nominally improved benefit in objective response rate (ORR), a secondary endpoint, favoring sac-TMT compared with TPC, but this was not formally tested under the prespecified analysis plan. The safety profile was consistent with what has been observed in previously reported studies of sac-TMT; no new safety signals were observed.

"Sac-TMT is the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. "There is a tremendous unmet need for therapies that can improve survival for these patients. We look forward to discussing these data with regulatory authorities and sharing with the scientific community on behalf of patients who may benefit."​

TroFuse-015 also marks the second positive Phase 3 study from Merck’s TroFuse clinical development program for sac-TMT. The program currently consists of 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The program is evaluating sac-TMT across a diverse range of tumor types, including endometrial, bladder, breast, cervical, gastric, non-small cell lung and ovarian cancers, and it spans early-to-late-stage disease as both monotherapy and in combination with immunotherapies. Within the program, 14 of the 18 Phase 3 studies are pursuing first-in-class opportunities to address unmet medical needs, including TroFuse-015.

About TroFuse-015
TroFuse-015 is a randomized, open-label, multicenter, global Phase 3 trial (ClinicalTrials.gov, NCT06356311) evaluating the efficacy and safety of the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) compared to the treatment of physician’s choice (TPC) in participants with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. The trial enrolled 473 patients who were randomized to receive either sac-TMT or TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Sac-TMT (4 mg/kg) was administered on Days 1, 15 and 29 of each six-week treatment cycle. Trifluridine-tipiracil (35 mg/m²) was administered orally twice daily on Days 1-5 and 8-12 of each four-week treatment cycle. Irinotecan (150 mg/m²) was administered on Days 1 and 15 of each four-week treatment cycle. Paclitaxel (80 mg/m²) was administered on Days 1, 8 and 15 of each four-week treatment cycle. Docetaxel (75 mg/m²) was administered on Day 1 of each three-week treatment cycle.

The study has a primary endpoint of overall survival. Secondary endpoints include progression-free survival, objective response rate, and duration of response.

About sacituzumab tirumotecan (sac-TMT)
Sac-TMT is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a unique bifunctional linker designed with the potential to maximize payload delivery to tumor cells and minimize payload loss while circulating in the body.

TROP2 is overexpressed on tumor cells compared to healthy cells in many common cancers, and through the TroFuse clinical development program, Merck is evaluating sac-TMT in 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The TroFuse development program spans early-to-late stage disease in more than nine disease areas and includes more than 15,000 patients worldwide. Numerous Phase 3 trials are exploring sac-TMT as monotherapy and in combination with immunotherapies, aiming to improve survival and quality of life for patients with advanced and earlier-stage cancers.

About Gastroesophageal Adenocarcinoma
Gastroesophageal adenocarcinoma comprises gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinomas (EAC).

Gastric (stomach) cancer often does not cause symptoms in its early stages, making it difficult to detect before the disease has advanced. Most gastric cancers are adenocarcinomas, accounting for approximately 90% to 95% of gastric malignancies, which develop from cells in the innermost lining of the stomach, known as the mucosa. In the U.S., it is estimated there will be approximately 31,500 new cases of gastric cancer and 10,700 deaths from the disease in 2026. Gastric cancer accounts for approximately 1.5% of all new cancers diagnosed in the U.S. each year.

Esophageal cancer starts when cells in the lining of the esophagus begin to grow out of control. In the U.S., about 68% of all new cases of esophageal cancer are EAC, and it is estimated there will be more than 14,300 new cases of EAC in 2026. Approximately 42% of EAC patients in the U.S. are diagnosed at the distant disease stage.

(Press release, Merck & Co, NOV 20, 2026, View Source [SID1234675036])

NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR Symposium

On November 20, 2026 NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company") reported new preclinical data showing that NUC-7738 enhanced the anti-cancer activity of carfilzomib, an approved proteasome inhibitor used to treat patients with multiple myeloma. The findings were presented at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18-20, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Carfilzomib works by inhibiting the proteasome, a cellular system that breaks down unwanted proteins. Multiple myeloma cells depend heavily on this system to manage their high protein load. NuCana believes that increasing the effectiveness of proteasome inhibition could make these cancer cells more vulnerable to treatment.

In three multiple myeloma cell lines, NUC-7738 demonstrated single-agent activity and increased the anti-cancer activity of carfilzomib. At concentrations where the individual agents left approximately half of the cells viable, the combination reduced cell viability to 3% in two models and 26% in the third after 96 hours. In two of the three models, the combination’s activity exceeded that expected if the two agents acted independently; in the third, the effect was additive. These findings provide a scientific rationale for NuCana to further investigate the combination in multiple myeloma.

Further studies showed that NUC-7738 altered proteasome function and increased the inhibition achieved with carfilzomib. In one model, proteasome activity after 24 hours was 25% of the untreated control with the combination, compared with 52% with carfilzomib alone. NuCana believes this demonstrates a measurable effect on the cellular system targeted by carfilzomib and may help explain the combination’s greater anti-cancer activity.

NuCana believes the findings also suggest an additional potential mode of action for NUC-7738. Although NUC-7738 initially increased proteasome activity when used on its own, it also reduced the processed form of NFE2L1, a protein involved in the cellular response to proteasome inhibition. Our research proposes that NUC-7738’s active metabolite may influence the opening of the proteasome’s gate, potentially increasing access for carfilzomib. These observations offer a basis for investigating how NUC-7738 may increase cancer cells’ sensitivity to proteasome inhibitors. Further studies are needed to test this proposed mode of action and assess its relevance to treatment in patients.

NuCana believes these results also support further investigation beyond multiple myeloma. In a separate laboratory screen evaluating NUC-7738 with 70 partner drugs across 35 cancer cell lines, carfilzomib ranked first on a measure of greater-than-expected combination activity. Such activity was observed in 28 of 33 solid-tumor models spanning 14 tumor types, at a single concentration of NUC-7738. These findings highlight the broad anti-cancer potential of NUC-7738 and supports further evaluation to identify the cancer indications in which the combination may offer the greatest potential.

"These findings add an important dimension to our understanding of NUC-7738’s mode of action," said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. "What is particularly encouraging is that the changes in proteasome function were accompanied by greater-than-expected anti-cancer activity in these preclinical models. We believe these data strengthen the rationale for further evaluation of NUC-7738 in combination with proteasome inhibitors and across additional tumor types."

Mr. Griffith continued: "Our priority is to define the optimal clinical development path for NUC-7738 in melanoma, informed by the forthcoming Phase 2 results and the latest translational data. We are also continuing our dialogue with the FDA regarding a potential registrational strategy. In parallel, we believe these new preclinical findings strengthen the scientific rationale for broadening the development of NUC-7738 beyond PD-1 inhibitor-resistant melanoma, through additional indications and combination strategies. With cash resources anticipated to fund our planned operations into 2029, we are focused on advancing these priorities and selecting the most promising opportunities for further development."

As previously announced, NuCana plans to present final results from the Phase 2 expansion cohort of the NuTide:701 study, evaluating NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma, together with the latest translational data, at the ESMO (Free ESMO Whitepaper) Immuno-Oncology & Advanced Therapies Congress in London from December 14–16, 2026.

Details of NuCana’s presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium are as follows:

Abstract Title: NUC-7738 Alters Functional Proteasome Activity and Enhances Carfilzomib Sensitivity in Multiple Myeloma

Poster Number: PB-084

Topic: Combination Therapies

Date: Friday, November 20, 2026

Presenting Author: Dr. Mustafa Elshani

More information regarding the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium can be found at:

View Source

(Press release, Nucana, NOV 20, 2026, View Source [SID1234675037])

PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors

On November 20, 2026 PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, reported updated results from the pivotal Phase 2 portion of the PYNNACLE clinical trial of rezatapopt monotherapy in patients with TP53 Y220C-mutated advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data presented include investigator-assessed efficacy across all tumor types, including the primary analysis population of 65 platinum-resistant/refractory ovarian cancer patients who received prior standard of care. In this group, the overall response rate (ORR) was 48%, with a median duration of response of 10.4 months. In the overall population across all cohorts among 168 evaluable patients, the ORR was 36% and the median duration of response was 8.1 months.

Results were presented today in a late breaking oral presentation by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain.

"Patients with platinum-resistant ovarian cancer who have progressed on standard therapies have few treatment options," said Dr. Schram. "In this heavily pretreated population, nearly half of patients with platinum-resistant/refractory ovarian cancer responded to rezatapopt, and those responses lasted a median of more than 10 months. These results support rezatapopt as a potential new targeted option for patients whose tumors harbor a TP53 Y220C mutation."

"The primary analysis reinforces the consistent, durable activity of rezatapopt in patients with platinum-resistant ovarian cancer that has been observed throughout the study," said Deepika Jalota, Pharm.D., Chief Development Officer of PMV Pharma. "For patients who have endured multiple rounds of chemotherapy, rezatapopt has the potential to be a single-agent, chemotherapy-free, once-daily oral option they can take at home. We expect to submit our NDA for accelerated approval in the first quarter of 2027."

The Phase 2 clinical trial data as of a September 4, 2026 data cutoff date are summarized below:

Patient Population

•
The safety population consisted of 180 patients across tumor types, including 113 ovarian cancer patients, treated with at least one dose of rezatapopt 2000 mg once daily as monotherapy.

•
The efficacy population consisted of 168 patients, including 101 ovarian cancer patients, treated with at least one dose of rezatapopt as of the data cutoff date and either had ≥1 post-baseline tumor assessment or discontinued early.

•
In the overall population, patients received a median of 3 prior lines of systemic therapy (range: 0-9) and median age was 65 years (range: 33-91).

•
In the ovarian cancer cohort, 93% of patients had high-grade serous ovarian cancer and 97% had platinum-resistant/refractory disease, with a median of 4 prior lines of systemic therapy (range: 1-9).

Efficacy Results

•
Confirmed responses were observed in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder cancers, and ampullary carcinoma.

•
In the primary analysis population of platinum-resistant/refractory ovarian cancer patients who had received prior standard of care, the investigator-assessed confirmed overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was 48% (31/65 patients, including one CR and 30 PRs), with a 10.4-month median duration of response and an 83% disease control rate.

•
A biomarker analysis revealed that, among 50 patients with available ctDNA data, 90% (45/50) achieved a ≥50% reduction in ctDNA levels of the TP53 Y220C VAF within 3-6 weeks of starting rezatapopt which supports the on-target activity of rezatapopt.

•
In the ovarian cancer population, responses were observed regardless of additional TP53 alterations or other oncogenic alterations at baseline.

•
In the overall population across all cohorts, a 36% ORR (61/168 patients, including four complete responses [CR], 53 partial responses [PR], and four unconfirmed partial responses [uPR]), with a median time to response of 1.3 months and a median duration of response of 8.1 months was observed.

•
The cohort-specific ORRs were as follows:

•
Ovarian cancer: 45% ORR (45/101 patients, including four confirmed CRs, 37 confirmed PRs, and four uPRs)

•
Lung cancer: 21% confirmed ORR (4/19 patients)

•
Breast cancer: 17% confirmed ORR (3/18 patients)

•
Endometrial cancer: 45% confirmed ORR (5/11 patients)

•
Other solid tumors: 21% confirmed ORR (4/19 patients)

Safety Results

•
Treatment-related adverse events (TRAEs) were mostly Grade 1 or 2 with the most frequent TRAEs observed (>15%) being nausea, fatigue, blood creatinine increase, vomiting, AST increase, ALT increase and anemia. The rates of individual Grade 3 TRAEs were ≤7.2%.
•
Lab abnormalities were manageable and monitorable, with most cases being transient and reversible.

•
Eleven patients (6%), including seven ovarian cancer patients, discontinued treatment due to TRAEs.

•
Rezatapopt continued to demonstrate a manageable safety profile.

About Rezatapopt

Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

About the PYNNACLE Clinical Trial

The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the clinical trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics, and effects on biomarkers were also assessed. The Phase 2 portion is a registrational, single arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C advanced solid tumors, conducted across approximately 70 sites.

For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750).

(Press release, PMV Pharma, NOV 20, 2026, View Source [SID1234675039])